Dr. Thomas H. Brannagan III, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 357
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: University of Virginia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NY license 194411 -
Electroneurodiagnostic Specialist/Technologist
NY license 194411
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
- Hospital for Special Surgery New York, NY
Medical groups
- Trustees of Columbia University in The City of New York (2,296 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 357
- Services billed
- 1,322
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 169 | 128 |
| Established patient office or other outpatient visit, 40-54 minutes | 161 | 126 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 146 | 111 |
| Needle measurement of electrical activity in arm or leg muscles, limited study | 135 | 86 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 68 | 54 |
| New patient office or other outpatient visit, 60-74 minutes | 54 | 54 |
| Nerve conduction, 11-12 studies | 51 | 51 |
| Nerve conduction, 13 or more studies | 51 | 50 |
| Nerve conduction, 9-10 studies | 41 | 41 |
| Established patient office or other outpatient visit, 20-29 minutes | 37 | 36 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pregabalin Other prescribers in New York, NY | 179 |
| Gamunex-C (immune globul g/gly/iga avg 46) | 142 |
| Gabapentin Other prescribers in New York, NY | 108 |
| Octagam (immun globg(igg)/malt/iga ov50) | 106 |
| Gammaked (immune globul g/gly/iga avg 46) | 79 |
| Privigen (immun glob g(igg)/pro/iga 0-50) | 77 |
| Lamotrigine Other prescribers in New York, NY | 75 |
| Oxcarbazepine Other prescribers in New York, NY | 68 |
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in New York, NY | 57 |
| Gammagard Liquid (immun glob g(igg)/gly/iga ov50) | 50 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 59 payments worth $21,281 in total to this clinician.
| Genzyme Corporation | $8,154 |
|---|---|
| Grifols USA, LLC | $7,574 |
| AstraZeneca Pharmaceuticals LP | $4,199 |
| Argenx US, Inc. | $519 |
| Alnylam Pharmaceuticals Inc. | $303 |
| Grifols Shared Services North America, Inc. | $295 |
| Takeda Pharmaceuticals U.S.A., Inc. | $103 |
| Janssen Biotech, Inc. | $42.77 |
| Consulting Fee | $9,222 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $8,154 |
| Food and Beverage | $3,105 |
| Travel and Lodging | $799 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $8,154 |
| Grifols USA, LLC Nov 22, 2025 | Consulting Fee Gamunex-C · Immunology and Neurology | $6,000 |
| AstraZeneca Pharmaceuticals LP Mar 2, 2025 | Consulting Fee WAINUA · Cardiovascular and Metabolism | $1,611 |
| AstraZeneca Pharmaceuticals LP Jun 3, 2025 | Consulting Fee WAINUA · Cardiovascular and Metabolism | $1,611 |
| Grifols USA, LLC Nov 22, 2025 | Travel and Lodging Gamunex-C · Immunology and Neurology · travel to Raleigh, NC · in-kind | $496 |
| Grifols USA, LLC Nov 22, 2025 | Travel and Lodging Gamunex-C · Immunology and Neurology · travel to Raleigh, NC · in-kind | $303 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 6 companies. The companies reported $231,410 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated - A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Sanofi US Services Inc. · Active, not recruiting · NCT06290128 - A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated - Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
Regeneron Pharmaceuticals, Inc. · Completed · NCT06593600 - A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi US Services Inc. · Recruiting · NCT06290141 - Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi US Services Inc. · Completed · NCT04658472 - HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Alnylam Pharmaceuticals Inc. - Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Janssen Research & Development, LLC - Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Argenx US, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.